Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or antagonist.
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
Systems and methods related to drug delivery are provided. In one arrangement, a fluid is administered to a subject in drinkable form, which can partially or fully solidify in the stomach or another area of the gastrointestinal tract to form a drug release article or composition.
Described herein are high-throughput platforms and methods of using the platforms that enable the identification of cellular and molecular interactions in high-throughput screens.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
An apparatus for facilitating quantitative anatomic pathology using mass spectrometry imaging includes a solid support having at least one flat surface, a tissue homogenate having a thickness mounted to the at least one flat surface of the solid support, and a quantitative array having a thickness and comprising a tissue microarray having a plurality of wells and a series of varying concentrations of an isotopically labeled metabolite deposited in the plurality of wells. The quantitative array is mounted over the tissue homogenate on the solid support.
The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
In accordance with an aspect of the present disclosure, a tissue extraction device may include a bag having an interior and a plurality of cutting elements extending through the interior of the bag.
A61B 17/221 - Calculus gripping devices in the form of loops or baskets
A61B 10/02 - Instruments for taking cell samples or for biopsy
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
7.
BRANCHED POLY(-AMINO ESTERS) FOR THE DELIVERY OF NUCLEIC ACIDS
The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease.
The present disclosure provides branched poly(β-amino esters) (PBAEs) of Formula (I) made by reacting primary amines with diacrylates. Further provided herein are compositions comprising the polymers of Formula (I), and methods of using the compositions and polymers as described herein for the treatment of disease.
The present disclosure provides, inter alia, compositions and methods for detecting changes in level of expression of cell-surface Type 2 terminal lactosamines on a population of cultured cells propagated under different conditions. The disclosure also provides compositions and methods for enforcing stably expressed glycans on human cells. In certain embodiments, the compositions and/or methods utilize one or more members of the α(1,3)-fucosyltransferase family. In certain embodiments, glycoengineered CD44 glycosylated product (e.g. HCELL) is stable for at least 48 hours at 4° C., with retained expression after cell cryopreservation.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
9.
TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE
The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. Disclosed are novel gene dependencies in the pathogenic immune cell state. Also, disclosed are methods for modifying immune cells characterized by the pathogenic immune cell state.
A method for tracking the location of a tissue mass comprising disposing a J-bar and electrical lead assembly within a needle cannula lumen; disposing the needle cannula within an outer cannula lumen; inserting the outer cannula into the anatomy of the patient; moving the needle cannula distally relative to the outer cannula; applying a force so that the J-bar and electrical lead assembly moves distally such that the fiducial sensor is anchored proximate to the tissue mass; moving the outer cannula and needle cannula proximally in concert, until the distal end of the outer cannula and the distal end of the needle cannula are disposed at the surface of the skin; applying a force so that the expandable basket moves distally, such that the expandable basket is disposed at the surface of the patient's skin with the electrical lead extending between the fiducial sensor and the expandable basket.
A61B 6/12 - Arrangements for detecting or locating foreign bodies
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
Described in certain exemplary embodiments herein are engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and/or nucleus of cells. In certain embodiments, an engineered Acr polypeptide comprises an Acr polypeptide operatively coupled to a cargo delivery molecule, wherein the cargo delivery molecule is capable of binding or otherwise interacting with a pore-forming polypeptide. Also described in certain exemplary embodiments are methods of Acr delivery to cells via the engineered Acr polypeptides and delivery systems of the present disclosure.
Embodiments provide computer-implemented methods, systems, and media for estimating a subject's body composition from ultrasound. Images acquired at standardized sites (e.g., biceps, abdominal wall, quadriceps) are quality-gated and preprocessed (scale, denoise, normalization). A neural network segments tissue layers; features from the image and masks feed a predictor that outputs fat mass (FM), fat-free mass (FFM), and, in some embodiments, adiposity indices (e.g., preperitoneal fat thickness, visceral-to-subcutaneous ratio). Multi-site predictions may be fused. The system can compute uncertainty, produce explanation overlays, and generate a report with values and visit-to-visit trends. An acquisition-planning module selects a minimal site subset to meet an error target. Implementations support edge/cloud inference and optional fusion with clinical covariates or laboratory data. The approach applies to neonatal, pediatric, adult, pregnant, and diabetic subjects for prenatal nutrition care, metabolic screening, and longitudinal monitoring.
The disclosure provides methods to facilitate the diagnosis of prostate cancer. In particular, the methods disclosed herein can be used to distinguish prostate cancer from benign prostatic hyperplasia. The methods comprise determining in a sample of the subject a level of one or more biomarkers selected from the group consisting of: mucin 3 (MUC3); pepsinogen 3 preproprotein (PGA3); β-2-microglobulin (β2M); PIK3IP1; uromodulin; prion protein; apolipoprotein D; WAP four-disulfide core domain protein 2; kininogen 1 variant; collagen alpha-1(III) chain; osteopontin-c (OPN-c); epidermal growth factor (beta-urogastrone); unnamed protein product (GI 158261423); cadherin-13 isoform 1 preproprotein; collagen alpha 1 chain precursor variant; ankyrin repeat domain-containing protein 11; pro-alpha 2(I) collagen; sulfatase 2 isoform b precursor; MASP-2 protein; Inositol 1,4,5-triphosphate receptor, type 2, isoform CRA_b; unnamed protein product (GI 47077082); alpha-1-acid glycoprotein 1 precursor; Zinc-alpha-2-glycoprotein precursor (ZAG); HSCARG protein, isoform CRA_b; alpha2-HS glycoprotein; and SNC66 protein, and correlating the level of the one or more biomarkers to a reference level to facilitate diagnosis of prostate cancer or BPH.
Disclosed herein are methods for of preventing a human immunodeficiency virus (HIV) infection in a subject or treating a subject suffering from an infectious disease caused by HIV, comprising administering to the subject an effective amount of a killer cell lectin-like receptor G1 (KLRG1) antagonist. The methods can further comprise administering other therapies to the subject, such as an anti-viral therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Compositions and methods for detecting bacterial pathogens containing microbial resistance genes in a sample, as well as methods for selecting a treatment for human infections involving such organisms. The methods involve carrying out a series of reactions in parallel where each reaction involves detecting a bacterial species or resistance gene in a sample using a CRISPR-Cas13a reaction. In some embodiments, the methods involve culturing a blood sample to increase the concentration of bacteria in the sample and/or direct detection of bacterial pathogens and/or microbial resistance genes in a blood sample.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
16.
DEVICES, CHROMATOGRAPHY COLUMNS, METHODS FOR AUTOMATED CHROMATOGRAPHY IN PARALLEL AND METHODS FOR PURIFICATION OF EXTRACELLULAR VESICLES
The technology described herein is directed to devices and methods for automated chromatography analysis of multiple samples in parallel. The devices include a pump, a computing device, and a stand having an upper portion including columns containing a resin and a bottom portion including wells or tubes. The invention also provides disclosures for chromatography columns and methods for purification of extracellular vesicles from a biological sample.
C12N 5/078 - Cells from blood or from the immune system
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
B01D 15/34 - Size-selective separation, e.g. size-exclusion chromatographyGel filtrationPermeation
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
17.
SYSTEMS AND METHODS FOR REAL TIME, QUANTITATIVE, HYPERSPECTRAL AND OPTICAL PROPERTY IMAGING FOR IN VIVO INTRAOPERATIVE MULTIPLEX MOLECULAR GUIDED SURGERY
Board of Regents, The University of Texas System (USA)
William Marsh Rice University (USA)
The Brigham and Women’s Hospital, Inc. (USA)
Inventor
Quevedo, Pablo Valdes
Veeraraghavan, Ashok
Kotwal, Alankar
Saragadam, Vishwanath
Bernstock, Joshua D.
Abstract
A method of the present disclosure, among others, involves illuminating a tissue sample with light across both a visible wavelength range and a near-infrared wavelength range, wherein the tissue sample has been administered with at least one fluorescent agent; acquiring a snapshot image of the tissue sample, wherein pixels of the snapshot image capture different 2D views of the tissue sample at a same time along with multiple wavelengths of light incident on a respective sensor pixel; creating a hyperspectral image cube of the tissue sample from the snapshot image; performing spectrally-resolved quantitative fluorescence measurements on the hyperspectral image cube; analyzing the spectrally-resolved quantitative fluorescence measurements to detect a presence of at least one fluorescent agent in the tissue sample; and/or identifying an optical fingerprint of an abnormal region of the tissue sample based on the detected at least one fluorescent agent in the tissue sample.
In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.
Provided herein are methods that use gene transcription levels to quantify mammalian expected total lifespan, remaining lifespan, chronological age and lifespan-adjusted biological age and predict whether an intervention will be protective or damaging to lifespan and health outcomes.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
20.
COMPOSITIONS AND METHODS FOR TREHALOSE PHOSPHOLIPIDS
Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.
A bioink formulation for digital light processing bioprinting comprising a mixture of a biocompatible cleavable polymer precursor, a biocompatible non-cleavable polymer precursor, and a photoinitiator is described. Three-dimensional (3D) objects prepared using these bioink formulations are also described. In addition, a method of 3D bioprinting is described. The method includes providing a bioink formulation in a 3D bioprinter vat; repeatedly photoactivating the biocompatible photoactive polymer precursors in the 3D bioprinter vat on a build plate immersed in the vat to form a 3D bioprinted object comprising polymers having a series of predefined shapes across the vertical direction based on a set of sliced images; and treating the 3D bioprinted object with an agent that cleaves chemical bonds within the cleavable polymer.
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
B29C 64/129 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask
B33Y 40/20 - Post-treatment, e.g. curing, coating or polishing
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
B33Y 80/00 - Products made by additive manufacturing
C08F 291/12 - Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds according to more than one of the groups on to nitrogen-containing macromolecules
C09D 4/06 - Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond in combination with a macromolecular compound other than an unsaturated polymer of groups
C09D 151/08 - Coating compositions based on graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bondsCoating compositions based on derivatives of such polymers grafted on to macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
23.
AUTOMATED EVALUATION OF QUALITY ASSURANCE METRICS FOR ASSISTED REPRODUCTION PROCEDURES
Systems and methods are provided for assigning a quality parameter to a reproductive cellular structure. An image of the reproductive cellular structure is obtained. The image of the reproductive cellular structure is provided to a neural network to generate a value representing a morphology of the reproductive cellular structure. The value is compared to a predefined standard to provide a quality assurance metric representing one of a medical personnel, a facility, a growth medium, and an identity of the reproductive cellular structure.
The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.
Provided herein are methods that use methylation of causal CpG sites to quantify aging and predict whether an intervention will be protective or damaging to the aging process.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and/or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The invention features a mucosal coating composition including: (i) water: (ii) at least one mucoadhesive polymer/polysaccharide (e.g., a concentration between 0.1-20% w/v); and (iii) at least one surfactant (e.g., a concentration between 0.005-5% w/v). Exhibit long-lasting residence times on mucosal tissues and prophylactic protection against transmucosal pathogens.
C40B 20/04 - Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
Compositions comprising peptides that bind specifically to BΔg (deglycosylated brevican), and methods of use thereof to deliver therapeutic and diagnostic agents to brevican-expressing cells, e.g., cancerous cells, e.g., brain cancer cells, e.g., glioblastoma cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Compositions comprising memory T cell Targeting Constructs comprising an anti-T cell antibody or antigen-binding portion thereof linked to a near-infrared photoactivated cytotoxin, e.g., a photoactive adduct of an infrared dye, and methods of use thereof for reducing numbers of pathogenic T cells selectively in peripheral tissues e.g., for treating inflammatory and autoimmune diseases.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
METHOD OF TREATING OR INHIBITING GLUCOSE INTOLERANCE
Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.
In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is directed to antibodies that interact with DLL4 and inhibit it from binding to NOTCH receptors. The invention also includes nucleic acids encoding the antibodies and methods of using the antibodies in research and in the prevention or treatment of various diseases and conditions.
Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor (NRI) and a muscarinic receptor antagonist.
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer and infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
LEIBNIZ-INSTITUT FÜR IMMUNTHERAPIE (LIT) (Germany)
The Brigham and Women's Hospital Inc. (USA)
Inventor
Gattinoni, Luca
Baldwin, Jeremy
Fioravanti, Jessica
Sengupta, Shiladitya
Saha, Tanmoy
Abstract
The present invention relates to compositions and methods in the context of mitochondrial transfer. Disclosed herein are methods that enable the efficient transfer of mitochondria from a donor cell to a recipient cell. The mitochondria-augmented cells are useful in the treatment of diseases and disorders, such as cancer. The present invention also relates to the molecular machinery involved in mitochondrial transfer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
39.
DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION
Disclosed are sustained biodegradable implant (a depot) that releases high drug doses directly into the tumor for treating cancer. The depot comprises a biodegradable polymer and a STING agonist and/or a PARP inhibitor (PARPi); wherein the STING agonist or the PARPi is distributed in the biodegradable polymer. The depot activates anticancer innate and adaptive immunity within the tumor microenvironment and promote immune infiltration of secondary, metastatic sites.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 35/04 - Antineoplastic agents specific for metastasis
40.
RECOMBINANT HERPES SIMPLEX VIRUS-2 EXPRESSING GLYCOPROTEIN D AND B ANTIGENS
Provided herein are recombinant Herpes Simplex Virus-2 comprising sequences encoding glycoprotein D and B antigens, with two sequences encoding dominant negative UL9 proteins, compositions comprising the same, and methods of use thereof.
Self-actuating articles including, for example, self-actuating needles and/or self-actuating biopsy punches, are generally provided. Advantageously, the self-actuating articles described herein may be useful as a general platform for delivery of a wide variety of pharmaceutical drugs that are typically delivered via injection directly into tissue due to degradation in the GI tract. The self-actuating articles described herein may also be used to deliver sensors and/or take biopsies without the need for an endoscopy. In some embodiments, the article comprises a spring (e.g., a coil spring, a beam, a material having particular mechanical recovery characteristics). Those of ordinary skill in the art would understand that the term spring is not intended to be limited to coil springs, but generally encompass any reversibly compressive material and/or component which, after releasing an applied compressive force on the material/component, the material/component substantially returns to an uncompressed length of the material/component (e.g., the within 95% of the length of the material/component prior to compression).
The Board of Trustees of the Leland Stanford Junior University (USA)
The Brigham and Women's Hospital, Inc. (USA)
Inventor
Schnitzler, Gavin Reinhardt
Engreitz, Jesse Michael
Kang, Helen Yihua
Ma, Xueyan Rosa
Gupta, Rajat Mohan
Abstract
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vascular disease in a subject involving administering a therapy to disrupt the cerebral cavernous malformation (CCM) signaling pathway in endothelial cells (e.g., arterial endothelial cells) in the subject. Also provided are methods of determining the likelihood that a subject will respond to a therapy for a vascular disease such as CAD, based on the identification of one or more loss-of-function variants in a CCM pathway associated gene in the subject.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
43.
TOPICAL ROSIGLITAZONE FOR RADIATION-INDUCED SKIN INJURY
While primary lymphedema is rare, numerous cancer patients develop secondary lymphedema, or the retention of lymphatic fluid. Lymphedema is characterized by progressive, irreversible fibroadipose tissue deposition. Non-surgical approaches such as compression therapy are the most common strategies to address lymphedema but are inadequate in the long term. Surgical procedures can reconstitute lymphatic drainage, but this approach is not curative. A new approach is needed to mitigate fibroadipose tissue deposition in lymphedema.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
The present invention provides a method to identify and use compounds for the inhibition of abnormal or dysregulated hepatic glucose production that results in elevated blood glucose levels and associated metabolic disorders. The invention is based on the surprising discovery that the glucagon forms an obligate binding complex with aP2, which is necessary for activation of the glucagon G-coupled protein receptor.
Determining a patient-level clinical endpoint prediction based on analysis of a three-dimensional volumetric image is discussed. One example method includes generating a set of patches from a volumetric image of a tissue sample. The method also includes employing a pretrained feature encoder to extract a set of features from the set of patches. The method additionally includes generating a volume-level feature associated with the volumetric image via an aggregation based on the set of features. The method further includes generating a clinical endpoint prediction based on the volume-level feature.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
46.
METHOD OF DELIVERY OF FUSOGENIC ONCOLYTIC VIRUS AND THERAPEUTIC MOLECULES
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a method for treating cancer comprising administering to a subject in need thereof a checkpoint inhibitor in combination with a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the methods described herein is suitable for treatment of solid tumors, as well as other cancers.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
47.
COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY
Described herein are compositions and methods for treating a disease in a subject by administering delivery vectors that express artificial microRNAs, artificial microRNA clusters, and/or a combination of microRNA clusters and associated non-coding RNAs to the subject. Also described herein are methods for preparing artificial microRNAs and artificial microRNA clusters.
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/078 - Cells from blood or from the immune system
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are compositions and methods using a therapeutic agent targeting mTORCI and a therapeutic agent targeting MDK for treating a Tuberous Sclerosis Complex (TSC)-associated disease, e.g., Angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), or for treating sporadic LAM/AML. Also provided are methods of identifying subjects for treatment, e.g., with checkpoint inhibitors.
Embodiments disclosed herein provide compositions for increasing CCL3 and/or CCL4 interactions with CCR5 and/or CCR1 to enhance an immune response. Applicants identified specific interactions between CD8+ T cells and inflammatory monocytes/macrophages that change during tumor progression from small to medium to large tumors. The ligands CCL3 and CCL4 are expressed in a specific subset of T cells (CD8+ PD-1+ TIM3+ T cells). The receptors CCR5 and CCR1 are expressed in inflammatory monocytes/macrophages. Modulation or maintenance of these interactions can allow enhanced immune responses for treating cancer, as well as for vaccination.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
52.
SYSTEMS, DEVICES, AND METHODS FOR GENERATING MACHINE LEARNING MODELS AND USING THE MACHINE LEARNING MODELS FOR EARLY PREDICTION AND PREVENTION OF PREECLAMPSIA
Disclosed herein are methods and systems for determining risk of preeclampsia. The system can include (a) a computer comprising: (i) a processor; and (II) a memory, coupled to the processor, the memory storing a module comprising: (1) test data for a sample from a subject including values indicating a quantitative measure of one or more markers; (2) a classification rule which, based on values including the measurements, classifies the subject as being at risk of preeclampsia, wherein the classification rule is configured to have a sensitivity of at least 75%, at least 85% or at least 95%; and (3) computer executable instructions for implementing the classification rule on the test data.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
The present disclosure describes methods of treating a skin disorder in a subject in need thereof and methods of locally suppressing an immune response in a tissue of a subject in need thereof. The methods can include contacting a microneedle array comprising a plurality of microneedles with a skin surface of the subject, wherein the plurality of microneedles comprises: i) a degradable hyaluronic acid polymer comprising a disulfide bond, and ii) a therapeutic agent; and applying pressure on the microneedle array such that the plurality of microneedles penetrates the skin surface, thereby releasing the therapeutic agent beneath the skin surface while simultaneously capturing ISF for successive analysis.
This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas. The disclosure also relates to shear-thinning compositions comprising silicate nanoparticles, gelatin or a derivative thereof, and a contrast agent. In some examples, the shear-thinning compositions comprise about 1.5% to about 10% by weight of silicate nanoparticles and about 0.5% to about 6.75% by weight of gelatin or a derivative thereof.
The present disclosure provides include kits, compositions, and methods related to impaired respiratory health (e.g., diseases and conditions relating to lung injury). In particular, the present disclosure provides include kits, compositions, and methods for quantifying protein biomarkers associated with impaired respiratory health and assessing the risk of, monitoring, treating and/or preventing, interstitial lung diseases (ILDs).
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
56.
LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES
Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (IL-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
57.
ENPP1 GENE THERAPY FOR THE TREATMENT OF VASCULAR DISEASE
Provided herein are compositions and methods for gene therapy for disorders of arterial calcification as well as Generalized Arterial Calcification of Infancy (GACI). The methods include a gene addition strategy to deliver a DNA construct to target tissues (such as liver and smooth muscle cells) to express soluble recombinant ENPP1 (srENPP1) or transmembrane full-length recombinant ENPP1 (rENPP1).
Methods for single-cell sequencing of mitochondrial RNA are described. In some embodiments, the methods further involve the identification of malignant cells and/or characterization of tumor subclones in a biological sample.
The disclosure provides improved methods and devices to create a hammock effect to stabilize the urethra without creating an incision in the abdomen or the vagina, and without using a surgical mesh. Such implementations can also leave no permanent material in the body. The simplicity afforded by such procedures and methods permits treatment of patients on an outpatient basis, and avoids risks and disadvantages associated with the installation of a permanent mesh.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
60.
COMPOSITIONS AND METHODS TARGETING SAT1 FOR ENHANCING ANTI-TUMOR IMMUNITY DURING TUMOR PROGRESSION
YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (Israel)
Inventor
Kuchroo, Vijay K.
Purohit, Vinee
Yosef, Nir
Wagner, Allon
Anderson, Ana Carrizosa
Mangani, Davide
Abstract
Embodiments disclosed herein provide compositions for enhancing anti-tumor immunity for treating cancer by targeting the polyamine pathway, and in particular inhibiting the function of the polyamine catabolic enzyme Sat1. In embodiments, Sat1 inhibition is targeted to CD4+ T cells, in particular Tregs.
Provided herein are compositions comprising Escherichia coli (E. coli), Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum), and/or Ensifer meliloti (E. meliloti) and a first stabilizing excipient. Also provided herein are methods of delivering E. coli, S. boulardii, L. plantarum, and/or E. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.
Compositions for local delivery of a drug to an intracranial region, such as brain tissue or a brain tumor. Methods for locally delivering drug or therapy to an intracranial region. Compositions may include a hydrogel in which a chemotherapy drug or immunotherapy drug is dispersed. Kits that include compositions or solutions that may be combined to form compositions.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Kato, Takahisa
Hata, Nobuhiko
Kobayashi, Satoshi
King, Franklin
Ninni, Brian
Wollin, Daniel Arthur
Kibel, Adam Stuart
Abstract
The present disclosure relates to an apparatus and method for steering a continuum robot through an anatomy, including receiving an identification of a first target location; inserting the continuum robot into the anatomy; steering, during a first navigation, the continuum robot along a first path toward the first target location; storing, in a memory, location data of a plurality of points along the first path; receiving a selection of at least two points of the plurality of points; editing location data of the selected at least two points; and steering, during a second navigation, the continuum robot along a second path toward a second target location, with the second path differing from the first path based on the edit of the location data of the selected at least two points.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
64.
BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and L2 are each a linker; and E is an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to targets that are not the natural substrate of the kinase; accordingly, diseases or disorders may be treated or prevented with molecules of the present disclosure.
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
Disclosed are compositions including a pharmaceutical agent assembled with a lipid composition, wherein the lipid composition comprises a lipidoid having structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein Ra, Rb1, Rb2, Rb3, Rb4, n1 and n2 are as described herein.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
66.
AUTOANTIBODY BIOMARKERS FOR THE EARLY DETECTION OF OVARIAN CANCER
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
Inventor
Katchman, Benjamin
Anderson, Karen
Wallstrom, Garrick
Labaer, Joshua
Cramer, Daniel
Abstract
Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.
KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
70.
SYSTEMS AND METHODS FOR TRANSCLIVAL TUMOR-TREATING FIELDS
An implantable device comprises a first support plate; a plurality of electrodes disposed on an outer surface of the first support plate, and a second support plate configured to be removably attached to the first support plate, wherein the electrodes are configured to generate a tumor treating field within a body surface.
The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and L2 are each a linker; and E is an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to targets that are not the natural substrate of the kinase; accordingly, diseases or disorders may be treated or prevented with molecules of the present disclosure.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
72.
APPARATUS AND METHOD FOR MULTIMODAL DATA FUSION FOR ACCURATE DIAGNOSIS
According to some embodiments, a method comprises obtaining data in multiple modalities, including data in an image modality and data in a biomarker modality; obtaining one or more trained machine-learning models; generating a first multi-modality group from the data in multiple modalities, wherein the first multi-modality group includes data in at least the image modality and in the biomarker modality; generating a group of intermediate data, wherein generating the group of intermediate data includes inputting the first multi-modality group into a machine-learning model that has been trained to extract features from input multi-modality data and output the features as the intermediate data; and generating a first classification result based on at least the group of intermediate data, wherein generating the first classification result includes inputting the intermediate data into a machine-learning model that has been trained to output the classification result based on the group of intermediate data.
Some aspects of the present disclosure are generally related to injectable compositions, for example, for intratumoral drug delivery. In some embodiments, the injectable composition comprises a polymer configured to undergo a solution-gel transition when heated from room temperature to at or around body temperature, allowing for the injection of the injectable composition as a liquid with subsequent gelation to retain the composition at the injection location. In some embodiments, the injectable compositions may be capable of encapsulating radio-opaque label and/or a hydrophobic immunoadjuvant (e.g., imiquimod) at a concentration of greater than or equal to 0.5 mg/mL. Accordingly, some aspects of the present disclosure are related to the radio-opaque label facilitating visualization of the injectable composition during injection and/or the retention of the injectable composition at the injection location, allowing for localized and extended-release of the immunoadjuvant. Still other aspects are generally directed to related methods, kits, or the like.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The disclosure features methods and compositions for the treatment of perivascular fibrosis and other hypertensive diseases and conditions, cardiovascular diseases, and chronic kidney disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/00 - Drugs for disorders of the cardiovascular system
A drug delivery device for administration to a subject is provided. In some embodiments, the drug delivery device includes a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device also includes a trigger operatively associated with the potential energy source, where the trigger is configured to actuate at a predetermined location within the subject. The drug delivery device also includes a rupturable membrane disposed along a flow path extending between the reservoir and an outlet, where the membrane is configured to rupture when the trigger is actuated. Once the trigger is actuated, the potential energy from the potential energy source may be released to expel the active pharmaceutical ingredient in a jet through the outlet.
Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
77.
VERO CELL LINES STABLY EXPRESSING HSV ICP0 PROTEIN
Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.
The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor, wherein the subject has a TET2 and/or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and/or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and/or DNMT3A, if it is determined that the subject has at least one TET2 and/or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and/or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Engineered ionophores capable of increased metal ion transport across hydrophobic membranes and/or reduced metal ion binding affinity, pharmaceutical compositions thereof, kits thereof, ion-selective membrane devices thereof, and methods of use thereof. Hydrophobic membranes can be biological, e.g., cell membranes, or nonbiological, e.g., ion-selective membranes. Engineered ionophores can comprise a metal ion chelator group comprising: a polar binding site having binding atoms to form a metal ion chelate complex; and one or more shielding group(s) in proximity to the binding atoms. Shielding groups can increase the hydrophobic membrane permeability and reduce the binding affinity of the chelate complex. Methods of use can comprise contacting said membranes with said engineered ionophores, metal ion chelate complexes thereof, pharmaceutical compositions thereof, the components of kits thereof, or the like, or any combination thereof. Methods of treatment comprise administering the same to a human or non-human animal, plant, or part thereof, e.g. cells.
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
The systems and methods described herein determine metrics of cardiac performance via a mechanical circulatory support device and use the cardiac performance to calibrate, control and deliver mechanical circulatory support for the heart. The systems include a controller configured to operate the device, receive inputs indicative of device operating conditions and hemodynamic parameters, and determine vascular performance, including vascular resistance and compliance, and native cardiac output. The systems and methods operate by using the mechanical circulatory support device (e.g., a heart pump) to introduce controlled perturbations of the vascular system and, in response, determine heart parameters such as stroke volume, vascular resistance and compliance, left ventricular end diastolic pressure, and ultimately determine native cardiac output.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
A61M 60/13 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel by means of a catheter allowing explantation, e.g. catheter pumps temporarily introduced via the vascular system
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
A61M 60/411 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being mechanical, e.g. transmitted by a shaft or cable generated by an electromotor
A61M 60/515 - Regulation using real-time patient data
A61M 60/523 - Regulation using real-time patient data using blood flow data, e.g. from blood flow transducers
A61M 60/531 - Regulation using real-time patient data using blood pressure data, e.g. from blood pressure sensors
A61M 60/538 - Regulation using real-time blood pump operational parameter data, e.g. motor current
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
81.
MULTIMODAL FOUNDATION MODEL FOR PATHOLOGY ANALYSIS
Systems and methods are provided for analysis of pathology data. Either a input data representing a pathology or a search query is received as an input and a first set of tokens is generated from the one of the input data representing a pathology and the search query from the input. The first set of tokens is matched to a second set of tokens at a multimodal fusion model trained on a pretraining dataset complied from a plurality of pathology-related sources. An output is provided based on the second set of tokens.
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/74 - Image or video pattern matchingProximity measures in feature spaces
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
82.
BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES
The present disclosure relates to bifunctional chemical conjugation molecules, which find utility as modifiers of target substrates. The present disclosure includes multifunctional compounds comprising an enzyme binding moiety, a chemical linker moiety, and a target binding moiety, which may further include an electrophilic reactive group. Molecules according to the present invention find use making substrate modifications such as post-translational modifications to proteins that are not the natural substrate of the enzyme. Diseases or disorders may be treated or prevented with molecules of the present disclosure.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present disclosure provides, inter alia, anti-peripheral lymph node address in antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
84.
SYSTEMS AND METHODS FOR ASSESSING OUTCOMES OF THE COMBINATION OF PREDICTIVE OR DESCRIPTIVE DATA MODELS
An improved patient monitoring system can include a processor device, a display, a first sensor in communication with the processor device, the first sensor being at least one of an electrocardiogram sensor, a pressure sensor, a blood oxygenation sensor, an image sensor, an impedance sensor, or a physiological sensor. The system can include a second sensor in communication with the processor device, the second sensor being a physiological sensor. The processor device can be configured to utilize the first accuracy, the second accuracy, the first correlation, the second correlation to determine a recommendation for fusing the first data model with the second data model.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to β-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to β-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in β-cells.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Systems and methods are provided for providing natural language decision support for pathology. A lower-dimensionality representation of each of a set of received pathology image is generated and a first set of tokens is generated from the representations of the set of pathology images by projecting the lower-dimensionality representations of the received pathology images to a same dimension as an embedding space of a large language model for text tokens or through multimodal blocks added to the large language model such as cross-attention. The large language model is trained on an instruction dataset complied from a plurality of pathology-related sources. A second set of tokens associated with a natural language prompt is received at the large language model. A response is determined from the first set of tokens and the second set of tokens at the large language model.
G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Described herein are methods for treating fibrosis, e.g., kidney fibrosis, using agents that target Secreted Modular Calcium-binding protein 2 (SMOC2).
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
88.
ISOLATION AND DIAGNOSTIC METHODS USING CELL TYPE-SPECIFIC AND/OR ORGAN-SPECIFIC EXTRACELLULAR VESICLE (EV) MARKERS
The present invention relates to novel biomarkers and combinations thereof for cell type-specific and/or organ-specific extracellular vesicles, in particular, brain-specific and/or neuron-specific extracellular vesicles. The present invention also provides methods for isolation and/or enrichment of cell type-specific and/or organ-specific extracellular vesicles, methods for identification of extracellular vesicles derived from a cell, and methods for diagnosing or prognosing a disorder, e.g., a neurodegenerative disorder, using the cell type specific and/or organ-specific extracellular vesicles. Compositions in the form of kits of reagents for detecting the cell type-specific and/or organ-specific extracellular vesicles are also provided.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Described in the present application are methods for preparing populations of hematopoietic stem cells (HSCs), e.g., autologous and/or allogenic HSCs, using mechanical stretching or Trpv4 agonists, and methods of use of the HSCs in transplantation. In some embodiments, the methods include providing a population comprising hemogenic endothelial (HE) cells, and (i) contacting the HE cells with an amount of an agonist of transient receptor potential cation channel-subfamily vanilloid member 4 (Trpv4); and/or (ii) subjecting the cells to cyclic 2-dimensional stretching, for a time and under conditions sufficient to stimulating endothelial-to-HSC transition. Also provided herein are methods for treating subjects who have, bone marrow, metabolic, and immune diseases; the methods include administering to the subject a therapeutically effective amount of hematopoietic stem cells (HSCs) obtained by a method described herein.
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
This disclosure relates to pectin-based polymer compositions and methods of use thereof to cover, protect, and seal injuries, e.g., surgical wounds, in a mesothelial tissue. The methods include obtaining a bioadhesive pectin-based polymer composition including a complex of high-methoxyl pectin (HMP) and carboxymethylcellulose (CMC) in a ratio from about 10 to 1 to 1 to 10 by weight; applying the composition to an injured mesothelial tissue; and applying pressure for at least one minute to enable the composition to bind to the mesothelial tissue.
A stereotactic system for attachment to a skull of a patient can include a mounting device that can include a mounting base configured to be attached to the skull, a sheath removably attached to the mounting base, a guide frame, and a guide member. The guide frame has a frame body that removably attaches to the mounting base and receives the sheath, a plurality of arms extending outwardly from the frame body, and a plurality of fiducials attached to the plurality of arms. The guide member is received within the frame body and receives the sheath such that the sheath is pivotable relative to the mounting base within the guide member. The guide member is configured to fixedly secure the sheath to the mounting base.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 1/317 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes for bones or joints, e.g. osteoscopes, arthroscopes
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
94.
SYSTEM AND METHOD FOR PROTEIN CORONA SENSOR ARRAY FOR EARLY DETECTION OF DISEASES
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Provided herein are methods and compositions for determining if a subject diagnosed with a CEACAM1-related disease or disorder is administered a CEACAM1 antibody or antigen-binding agent as a treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
96.
ROBOTIC CATHETER SYSTEM AND METHOD OF REPLAYING TARGETING TRAJECTORY
THE BRIGHAM AND WOMEN'S HOSPITAL INCORPORATED (USA)
Inventor
Masaki, Fumitaro
Ninni, Brian
King, Franklin
Hata, Nobuhiko
Abstract
A system for, display controller connected to, and a method of, operating a robotic catheter system which is configured to manipulate a catheter having one or more bending segments along the catheter's length and a catheter tip at the distal end thereof, and which includes an actuator unit coupled to the bending segments via one or more drive wires arranged along a wall of the catheter. The method comprising: inserting at least part of the catheter into a lumen along an insertion trajectory that spans from an insertion point to a target; causing the actuator unit to actuate at least one of the one or more drive wires to align the catheter tip with the target; determining the position and/or orientation of the catheter tip with respect to the target; and displaying information about an accuracy of alignment between the catheter tip with respect to the target.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
97.
DETERMINING WHETHER AN IBD PATIENT WILL RESPOND TO 5-ASA THERAPY
The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
98.
SYSTEMS AND METHODS FOR STIMULATION, NERVE REPAIR AND/OR DRUG DELIVERY
Systems and methods for nerve repair can include a polymer configured to form an elongated conduit to receive an in vivo nerve therein and provide a mechanical stabilization to the in vivo nerve. The polymer can be configured to degrade upon being subjected to a dissolution solution to remove the mechanical stabilization from the in vivo nerve.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 17/00 - Surgical instruments, devices or methods
Some aspects of the present disclosure are related to articles for measuring electrical signals internal to a subject, e.g., of the gastrointestinal tract (GI tract). The articles, in some embodiments, are ingestible and/or implantable. In some embodiments, the articles comprise a substrate comprising a plurality of electrodes, the substrate having a Young's elastic modulus of greater than or equal to 0.01 MPa and less than or equal to 200 MPa. In some such cases, the Young's elastic modulus of the substrate facilitates elastic recoil of the substrate such that at least a portion of the plurality of electrodes contact a surface of a tissue at the location internal to the subject (e.g., the GI tract) and thus facilitate measurement of electrical signals at the location internal to the subject. Other aspects are related to methods of using the articles, for example, to monitor electrical signals from the location internal to the subject.
A medical information processing apparatus according to an embodiment includes a first analysis unit, a second analysis unit, a determination unit, and a third analysis unit. The first analysis unit executes a first analysis based on a medical image of a subject. The second analysis unit executes a second analysis based on a specimen examination result of the subject. The determination unit determines a matching degree between the result of the first analysis by the first analysis unit and the result of the second analysis by the second analysis unit. The third analysis unit executes a third analysis based on the medical image and the specimen examination result according to analysis conditions based on the determination result of the matching degree by the determination unit, and determines diagnosis support information based on the medical image and the specimen examination result.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
patents
